Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
https://www.zacks.com/stock/news/2240686/buy-5-medical-devices-stocks-for-a-stable-portfolio-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240686
Mar 14, 2024 - We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
0
Community Health (CYH), Cost Plus Drugs Unite to Lower Drug Cost
https://www.zacks.com/stock/news/2237878/community-health-cyh-cost-plus-drugs-unite-to-lower-drug-cost?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237878
Mar 08, 2024 - Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.
0
DaVita (DVA) Expands Operational Footprint Via New Agreement
https://www.zacks.com/stock/news/2236716/davita-dva-expands-operational-footprint-via-new-agreement?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236716
Mar 06, 2024 - DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
0
DexCom (DXCM) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2235686/dexcom-dxcm-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2235686
Mar 04, 2024 - In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.
0
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
https://www.zacks.com/stock/news/2231836/clearpoint-neuro-clpt-gets-fda-s-nod-for-new-software?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2231836
Feb 26, 2024 - ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
0
2 No-Brainer Healthcare Stocks to Buy Right Now
https://www.fool.com/investing/2024/02/10/2-no-brainer-healthcare-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 10, 2024 - Companies in the healthcare industry tend to generate returns in a wide range of market environments.
0
DexCom (DXCM) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/08/dexcom-dxcm-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Feb 08, 2024 - DXCM earnings call for the period ending December 31, 2023.
0
DexCom (DXCM) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2223683/dexcom-dxcm-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2223683
Feb 08, 2024 - The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Curious about DexCom (DXCM) Q4 Performance? Explore Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2220910/curious-about-dexcom-dxcm-q4-performance-explore-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2220910
Feb 05, 2024 - Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
0
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
https://www.zacks.com/stock/news/2219585/dexcom-dxcm-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2219585
Feb 01, 2024 - DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0